Latest News for: b-cell leukemia

Edit

THIS protector protein helps hair regrowth in adults: Know how it works

The Times of India 01 Apr 2025
The researchers have examined the role of MCL-1 proteinMCL-1 (Myeloid Cell Leukemia-1) is an anti-apoptotic protein belonging to the BCL-2 family. It plays a crucial role in cell survival by inhibiting programmed cell death (apoptosis).
Edit

Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, ...

GetNews 28 Mar 2025
"Peripheral T-cell Lymphoma Market" ... The exact cause of PTCL remains unclear, but genetic mutations, viral infections (such as Epstein-Barr virus and human T-cell leukemia virus), and immune system dysfunction are considered potential risk factors.
Edit

Acute Lymphocytic Leukemia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ...

GetNews 26 Mar 2025
UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Edit

De novo discovery of a molecular glue–like macrocyclic peptide that induces MCL1 homodimerization

PNAS 25 Mar 2025
... myeloid cell leukemia 1 (MCL1), a critical antiapoptotic protein.
Edit

Two Boys Cancer — One Town’s Help

Weekly Villager 25 Mar 2025
Newton Falls, Ohio is often thought of as an idyllic small town ... Ribbon ... The lad then underwent 27 biopsy procedures leading to the diagnosis B-Cell Leukemia ... Jude Hero 5K in his honor ... He has since been diagnosed with T-Cell Lymphoma/Blastic Leukemia ... .
Edit

B-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 24 Mar 2025
MB-CART20.1 is an investigational CAR-T cell therapy engineered to target the CD20 protein, which is highly expressed on the surface of B-cells in certain cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Edit

UAE: Private cord blood banking services launched in Abu Dhabi with flexible payment plans

Khaleejtimes 24 Mar 2025
... prevalence in the UAE), sickle cell anemia (5.8 per cent), leukemia, lymphoma, bone marrow disorders, immune deficiencies, and genetic conditions" Abu Dhabi media office said in a statement on Monday.
Edit

UAE: Affordable private cord blood banking services launched in Abu Dhabi with flexible payment plans

Khaleejtimes 24 Mar 2025
... prevalence in the UAE), sickle cell anemia (5.8 per cent), leukemia, lymphoma, bone marrow disorders, immune deficiencies, and genetic conditions" Abu Dhabi media office said in a statement on Monday.
Edit

Abu Dhabi Biobank unveils private cord blood banking services

The Gulf Time 24 Mar 2025
... rates in the UAE, including thalassemia (16.5 percent prevalence in the UAE), sickle cell anemia (5.8 percent), leukemia, lymphoma, bone marrow disorders, immune deficiencies, and genetic conditions.
Edit

Abu Dhabi Biobank launches private cord blood banking services

Urdu Point 24 Mar 2025
... rates in the UAE, including thalassemia (16.5 percent prevalence in the UAE), sickle cell anemia (5.8 percent), leukemia, lymphoma, bone marrow disorders, immune deficiencies, and genetic conditions.
Edit

Hemogenyx Pharmaceuticals PLC Announces First Patient Safety

ACCESSWIRE 24 Mar 2025
... successfully treated as part of the Company's Phase I clinical trial of HG-CT-1, the Company's proprietary CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML) in adults.
Edit

CBJ CannonBall event raised thousands for local youth and celebrated young heroes

The Columbus Dispatch 23 Mar 2025
For Smith, it was being diagnosed with acute lymphoblastic leukemia (ALL), a blood cancer that affects immature white blood cells called lymphocytes, after doctors believed he, like the rest of his family, simply had a bad case of the COVID-19 virus.
Edit

Nursery of the blood: How stem cells calm the body's immune response

Science Daily 21 Mar 2025
An international research team has now investigated the developmental pathways of blood cells in humans ... leukemia.
Edit

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

ACCESSWIRE 20 Mar 2025
Aptevo's wholly owned lead proprietary drug candidate, mipletamig, targeting AML, MDS and other leukemias, is differentiated by design to redirect the immune system of the patient to destroy leukemic ...
Edit

India’s first homegrown CAR T-Cell therapy shows 73% success rate against cancer

The Times of India 19 Mar 2025
... of B cells, including cancerous B cells in conditions like B-cell leukemia and lymphoma.These therapies recognize and attack CD19-positive cells, making them effective in treating B-cell malignancies.
×